Clinical Trial Update: Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial [Phase 3]

View source ↗

Summary

Open-label extension study assessing safety, tolerability, and activity of oral fampridine-SR in multiple sclerosis patients who previously participated in the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ampyra (fampridine-SR) (fampridine)

Snippet

Sponsor: Acorda Therapeutics | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2012-02-27